Safety and Performance of SoftOx Wound Irrigation Solution (SWIS) in Acute Wounds
Launched by SOFTOX SOLUTIONS AS · Nov 14, 2018
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
This is a pilot study with an open-label, exploratory study design with the aim to document preliminary safety and performance of the SoftOx Wound Irrigation Solution while used as intended by the manufacturer, i.e. as an irrigation solution for mechanical rinsing of breached or compromised skin as a result from acute wounds. This first-in-man study will give valuable information on the feasibility of the treatment with the SoftOx Wound Irrigation Solution to prepare for continuous studies in clinically significant settings prior CE marking. The investigation population will consist of 12 s...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 and older
- • 2. Non-healing, leg ulcers, that are scheduled for an operation with excision of the chronic leg ulcer and split skin transplantation
- • 3. Been informed of the nature, the scope and the relevance of the clinical investigation
- • 4. Voluntarily agreed to participation and has duly signed the Informed Consent Form
- Exclusion Criteria:
- • 1. Participating in any other clinical investigation
- • 2. On systemic immunomodulating drugs
- • 3. On systemic steroid treatment up to four (4) weeks prior to study inclusion
- • 4. On strong pain medication (e.g. opioids)
- • 5. Severe neuropathy (or dysesthesia on the donor site)
- • 6. Pregnancy
- • 7. Dementia
- • 8. Allergy to polyurethane foam, hypochlorous acid, acetic acid or any other remedies/material used in the clinical investigation
- • 9. Not able to read or understand Danish
- • 10. Any other conditions that as judged by the investigator may make follow-up or investigation inappropriate
- • 11. That according to the Declaration of Helsinki is deemed unsuitable for study enrolment
About Softox Solutions As
SoftOx Solutions AS is a pioneering biotechnology company focused on developing innovative antimicrobial solutions to address pressing healthcare challenges. With a commitment to enhancing patient outcomes and safety, the company leverages cutting-edge research and advanced technology to create effective treatments for infections and wound care. Through rigorous clinical trials and a robust pipeline of products, SoftOx Solutions AS aims to deliver safer alternatives to traditional antibiotics and contribute to the global fight against antimicrobial resistance. Their expertise in biochemistry and pharmacology positions them at the forefront of transforming infection management in clinical settings.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Ewa A Burian, MD
Principal Investigator
Bispebjerg Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials